Pricing and Reimbursement of Pharmaceuticals in Belgium

Abstract

The Belgian healthcare system has a tradition of access and equity at affordable prices. As in other countries, the system becomes pressured by increasing healthcare costs. This paper describes the actual situation in Belgium with special focus on pharmaceutical products and the potential role of pharmacoeconomics in decision making on price and reimbursement. Nearly all people in Belgium are covered by compulsory health insurance. The system is paid for by social security, the patients and the federal and regional authorities. The part of the consumption of pharmaceuticals that is charged to insurance was about 62.1 billion Belgian francs (BeF), i.e. about 50% of the pharmaceutical market in 1994. Price setting in Belgium has been rather low due to the positive reimbursement list, where the price of a new drug is compared to existing drugs in a comparable therapeutic class (so-called reimbursement criteria). The expenditure on pharmaceuticals is increasing faster than global funding for public health. In order to control drug budgets, different cost-containment measures have been or are being taken, i.e. a mix of price, reimbursement and volume controls. These cost-containment measures are not necessarily in accordance with a health economic approach. This paper suggests the scope for better implementation of pharmacoeconomic evaluation, which can lead to more flexible reimbursement systems in specific indications. Therefore, a formal recognition of the role of objective economic evaluations is needed for both hospital and ambulatory care. This process should be proceeded by improving the understanding and robustness of pharmacoeconomic evaluations.

Prices of antihypertensive medicines in sub-Saharan Africa and alignment to WHO’s model list of essential medicines

“…None of the 13 investigated countries has a mandatory social security or a national inclusive medical insurance covering the whole population (Annemans et al. 1997).…”

Multiple Criteria Decision Analysis for Health Technology Assessment

“…For example, the Netherlands health care system used four criteria (care must be necessary, effective, and efficient and cannot be left to the individual's own responsibility) for priority setting, but it made the decision-making process rather complex [26]. Some countries such as Belgium and France, in an attempt to establish a relationship between financial constraints and medical need, have proposed to vary their pharmaceutical expenditure on the basis of patients' medical need [27,28]. France classifies med-icines into three categories: essential, important, and convenience, and French people receive 100% reimbursement for essential drugs, 65% for important drugs, and 35% for convenience medication [28].…”

Cost-effectiveness of iodixanol in patients at high risk of contrast-induced nephropathy

“…In 1992, Australia was the first country to demand costeffectiveness information for drug reimbursement decisions [20]. Reimbursement authorities in many countries have followed the Australian example and more or less formal regulatory requirements for cost-effectiveness information can now be found in about 10 countries around the world [12,13,[21][22][23][24][25][26][27][28]. The increased influence of costeffectiveness on the pricing and reimbursement decision has made the evidence of costeffectiveness a fourth area where pharmaceutical companies now need to provide evidence [29,30].…”